Can dabigatran be used in pregnant women?

May 14, 2014

Using dabigatran anticoagulation treatment for pregnant women could potentially affect fetal blood coagulation, according to a study published in Obstetrics & Gynecology. Dabigatran may cross the placenta to the fetus.

Using dabigatran anticoagulation treatment for pregnant women could potentially affect fetal blood coagulation, according to a study published in Obstetrics & Gynecology. Dabigatran may cross the placenta to the fetus.

University of Toronto, Ontario, Canada, researchers conducted perfusion experiments by using 6 placentas from healthy term pregnancies after cesarean delivery.

As reported by Drug Topics, the researchers found evidence of the transfer of dabigatran and its prodrug dabigatran etexilate mesylate across the term human placenta from the mother to the fetus. These data suggest that, pending further study, dabigatran should not be used for anticoagulation of pregnant women, because the drug may have an adverse effect on fetal blood coagulation, the authors wrote.

“Researchers continue to gather more information regarding these new anticoagulants,” said FormularyWatch advisor James M. Wooten, PharmD, associate professor, department of medicine, section of clinical pharmacology, University of Missouri-Kansas City. 

“This information is very important since anticoagulation is sometimes necessary in pregnant women,” Dr Wooten said. “Because warfarin is contra-indicated in pregnancy, it was hoped that one of the new oral anticoagulants like dabigatran might be an alternative. This study demonstrates that dabigatran should also not be used in pregnancy.”

Dabigatran is a direct thrombin inhibitor, and it is unknown whether or not the other newer oral anticoagulants, which work by inhibiting factor Xa, will be contra-indicated as well, according to Dr Wooten. “Further study is necessary,” he said.

For more on this topic:

ACC: New findings presented on dabigatran antidote